Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Safe to take pregabalin and melatonin?

See the DrugPatentWatch profile for pregabalin

Is it generally safe to combine pregabalin and melatonin?

There is no single “universal” answer, because safety depends on your dose, other medicines, health conditions, and how you take them. Pregabalin can cause dizziness and sleepiness; melatonin can also make you feel drowsy. Taken together, they may increase sedation and impair alertness or coordination, so the main practical concern is heightened drowsiness, slowed reaction time, and falls—especially in older adults.

If you’re starting the combination (or restarting after a break), many clinicians advise using caution the first few nights and avoiding activities that require full alertness (driving, operating machinery) until you know how you respond.

What side effects should you watch for?

When pregabalin and melatonin are used together, people most often notice effects related to the nervous system and sleepiness, such as:
- Excess sleepiness or grogginess the next day
- Dizziness or lightheadedness
- Trouble concentrating
- Increased risk of imbalance or falls

Seek urgent care if you develop severe confusion, trouble staying awake, fainting, slow or irregular breathing, or any allergic symptoms (swelling of the face/lips, rash with breathing difficulty).

Who should be extra careful combining them?

Extra caution is common if you:
- Are older (higher fall risk with sedating meds)
- Have breathing problems (sleep apnea, chronic lung disease), or use other sedatives
- Take other medications that cause drowsiness, such as opioids, benzodiazepines (e.g., lorazepam, diazepam), “Z-drug” sleep meds, some antihistamines (e.g., diphenhydramine), or alcohol
- Have liver or kidney impairment (pregabalin dosing can be affected, and side effects may worsen)
- Have a history of falls or balance problems

Can melatonin change pregabalin levels or vice versa?

Melatonin is not known as a major driver of pregabalin blood-level changes the way some other drugs are, but that doesn’t remove the main risk: additive sleepiness. Even without major interaction in blood levels, the combined effects on alertness can still be significant.

What’s the safest way to try them together?

A common approach is:
- Start with the lowest effective melatonin dose (people often begin with a small dose rather than high-dose products)
- Take them at bedtime as directed for each medication
- Avoid alcohol and other sedating drugs during the adjustment period
- Give yourself time to see how you feel the next morning (don’t schedule important driving the next day until you know your response)

If pregabalin is newly started or recently increased, be more cautious because pregabalin itself can initially cause more dizziness and sedation.

When should you ask a clinician instead of self-combining?

Check with a pharmacist or prescribing clinician before combining if:
- You take other sedatives/opioids or drink alcohol regularly
- You have sleep apnea or lung disease
- You’ve had confusion, fainting, or falls before
- You’re using pregabalin for pain and plan to start melatonin for sleep, and the cause of insomnia hasn’t been addressed
- You have kidney disease or are unsure whether pregabalin dosing is appropriate

Sources

No drug-interaction or dosing/safety sources were provided in the prompt, and I don’t want to guess. If you share the doses you’re taking (pregabalin mg and how often, melatonin mg and timing), your age, and any other sedating medicines (including opioids/benzos/antihistamines), I can give more targeted safety considerations based on those details.



Other Questions About Pregabalin :

Price pregabalin 75 mg? Can pregabalin increase your pulse rate? Pregabalin can you drink alcohol? Pregabalin drug interaction with melatonin? Can pregabalin increase heart rate? Can pregabalin cause bradycardia? Pregabalin equivalent in herbs?

AI-Drug Label Prescribing Information Alignment Report

25
25%
Grade D

Poor

Not Aligned

Patient Risk: Moderate

Summary

The response makes many safety/interaction/administration-related claims about pregabalin and combining it with melatonin, but the provided FDA excerpts do not support most of these specific assertions. The response also includes melatonin-related claims, which are not addressed in the supplied pregabalin label excerpts, and several detailed safety events (e.g., fainting, slow/irregular breathing, severe confusion) are not supported by the provided text.


Category Scores

Indication
90
Excellent
Dosage
10
Poor
Warnings
30
Poor
DrugInteractions
25
Poor
SpecificPopulations
20
Poor
SpecificPopulations
20
Poor
Administration
15
Poor

Accurate Statements

Pregabalin can cause dizziness and somnolence.
Supported generally by 5.5 Dizziness and Somnolence: "Pregabalin extended-release tablets may cause dizziness and somnolence".
Concomitant use of pregabalin extended-release tablets with other CNS depressants may exacerbate dizziness and somnolence.
Supported by 5.5: "Concomitant use ... with other central nervous system (CNS) depressants may exacerbate these effects".
Opioids can be associated with increased risk when co-administered with pregabalin due to respiratory depression/sedation monitoring considerations.
Supported by 5.4 Respiratory Depression: pregabalin with CNS depressants including opioids; monitor for symptoms of respiratory depression and sedation.

Unsupported Statements

Melatonin can also cause drowsiness.
No melatonin information appears in the provided pregabalin prescribing information excerpts.
Taken together, pregabalin and melatonin may increase sedation.
The provided label excerpts do not mention melatonin or any pregabalin+melatonin interaction.
Taken together, pregabalin and melatonin may impair alertness / coordination / heightened drowsiness, slowed reaction time, and falls are main practical concerns (especially in older adults).
Specific claims about melatonin combination effects (alertness, coordination, falls, older adults) are not supported by the supplied label excerpts.
Using caution the first few nights when starting or restarting the combination is advised by many clinicians.
Not supported by the provided FDA excerpts (no clinician-guidance statements; no melatonin combination discussion).
Avoiding activities requiring full alertness (driving, operating machinery) until response is known is advised for the combination.
The provided excerpts do not include driving/operating machinery guidance or any melatonin-combination-specific counseling.
Excess sleepiness or grogginess the next day can occur with pregabalin and melatonin used together.
No melatonin combination support; provided excerpts only broadly support somnolence/dizziness.
Dizziness or lightheadedness can occur with pregabalin and melatonin used together / trouble concentrating can occur / increased risk of imbalance or falls can occur / trouble staying awake can occur / severe confusion can occur / fainting can occur / slow or irregular breathing can occur with the combination / allergic symptoms can occur with the combination (and detailed descriptions).
These specific adverse-event claims about pregabalin+melatonin use are not supported by the provided label excerpts.
Extra caution is common when combining pregabalin and melatonin in older adults due to higher fall risk with sedating medications.
The supplied label excerpts do not mention falls or melatonin combination caution.
Extra caution is common when combining pregabalin and melatonin in people with breathing problems (sleep apnea, chronic lung disease).
The supplied label excerpts mention respiratory impairment in general for respiratory depression risk, but do not mention sleep apnea/chronic lung disease nor any melatonin combination.
Extra caution is common when combining pregabalin and melatonin in people using other sedatives.
Partially related concept exists (CNS depressants may exacerbate sedation; 5.4/5.5), but the response frames it specifically as pregabalin+melatonin combination; melatonin is not addressed in the excerpts.
Benzodiazepines (e.g., lorazepam, diazepam) can cause drowsiness / 'Z-drug' sleep meds can cause drowsiness / some antihistamines (diphenhydramine) can cause drowsiness / alcohol can cause sedation.
The provided pregabalin label excerpts do not list these specific co-medicines or substantiate these specific examples.
Extra caution ... in people with liver or kidney impairment / Side effects may worsen with liver or kidney impairment when taking pregabalin.
The provided excerpts include renal impairment dosing guidance (5.2/8.5/2.5) but do not support liver-related caution or broad claims that side effects worsen with liver impairment.
Melatonin is not known as a major driver of pregabalin blood-level changes like some other drugs / additive sleepiness can still be significant even without major interaction in blood levels between melatonin and pregabalin.
No melatonin pharmacokinetic/interaction discussion is provided in the supplied label excerpts.
Starting with the lowest effective melatonin dose is recommended as a common approach / Taking pregabalin and melatonin at bedtime as directed for each medication is recommended / Avoiding alcohol and other sedating drugs during the adjustment period is recommended / Not scheduling important driving the next day until response is known is recommended as a common approach.
The pregabalin label excerpts do not provide melatonin dosing recommendations or combined bedtime/behavioral counseling.
Pregabalin can initially cause more dizziness and sedation when newly started or recently increased.
The supplied label excerpt does not contain this timing-specific statement; it only states may cause dizziness and somnolence and includes monitoring considerations generally.
Checking with a pharmacist or prescribing clinician before combining is advised if other sedatives/opioids are taken or alcohol is consumed regularly / if there is sleep apnea or lung disease / if there has been prior confusion, fainting, or falls / if pregabalin is being used for pain and melatonin is being started for sleep and the cause of insomnia has not been addressed / if there is kidney disease or uncertainty about whether pregabalin dosing is appropriate.
The supplied excerpts do not include melatonin-related counseling or the specific scenarios listed (confusion/fainting/falls/insomnia cause). Renal impairment guidance is present for pregabalin dosing, but the combined-use counseling is not supported.
Pregabalin dosing can be affected by kidney impairment.
While renal impairment guidance is present, this specific sentence is used in a broader unsupported set of claims; the excerpted label text provided does not explicitly support this wording as a standalone claim (beyond not being recommended for CLcr <30 mL/min or hemodialysis and that care is taken in dose selection).

Contradictions


Important Omissions

Pregabalin extended-release tablets should be administered once daily after an evening meal; should not be split/crushed/chewed; and missed-dose/taper/discontinuation instructions are specified in the label.
Importance: Moderate
Pregabalin extended-release tablets are contraindicated only for known hypersensitivity to pregabalin or components (and angioedema/hypersensitivity reactions management).
Importance: Moderate
Respiratory depression monitoring and sedation monitoring are specified when co-administered with CNS depressants and in underlying respiratory impairment; plus suicidal behavior monitoring is listed.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Many detailed adverse-event and combination-use claims about pregabalin+melatonin are unsupported by the provided label excerpts. While some general pregabalin CNS-depressant effects are supported (dizziness/somnolence; CNS depressants may exacerbate; respiratory depression risk with opioids/CNS depressants), the absence of label support for other claims and counseling could lead to inaccurate expectations or missed label-required administration/monitoring details.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
The response includes many melatonin-combination-specific safety and interaction claims (falls, fainting, severe confusion, slow/irregular breathing, etc.) and dosing/behavioral guidance that are not supported by the provided pregabalin label excerpts.

Suggested Improvement
Limit statements to what is supported in the provided label excerpts for pregabalin extended-release tablets (e.g., may cause dizziness/somnolence; concomitant CNS depressants may exacerbate effects; monitor for respiratory depression/sedation with opioids/CNS depressants; renal impairment dosing restriction). Remove melatonin-specific combination claims unless the label excerpts specifically address melatonin or pregabalin+melatonin coadministration.

Drug Brand Mention Assessment

Branding Score
39
Visibility
45
Mentioned
Ranking
#1
Sentiment
25
Recommendation Status
conditional
Brand Perception
Best Known For

additive sleepiness


Core Claims
  • Pregabalin can cause dizziness and sleepiness, and melatonin can also cause drowsiness
  • Taken together, they may increase sedation and impair alertness or coordination
  • A main concern is heightened drowsiness, slowed reaction time, and falls—especially in older adults
  • Clinicians advise using caution the first few nights and avoiding driving/operating machinery until you know how you respond
  • Even without major blood-level interaction, additive sleepiness can still be significant
Differentiators
  • Risk highlighted is additive drowsiness affecting alertness, reaction time, and coordination
  • Emphasis on higher fall risk, especially in older adults
  • Notes dosing/starting considerations (lowest effective melatonin dose and bedtime use)

Pricing Perception: Not Mentioned